A Changing Landscape: New and Pipeline HIV Therapies

Size: px
Start display at page:

Download "A Changing Landscape: New and Pipeline HIV Therapies"

Transcription

1 A Changing Landscape: New and Pipeline HIV Therapies Sarah Turley, PharmD, BCPS PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health System

2 Financial Disclosure I have no relevant finances to disclose.

3 Objectives Review updated guidelines for the management of human immunodeficiency virus (HIV) Discuss literature supporting new co formulated antiretroviral products Identify pipeline antiretroviral medications and current status in clinical investigations Evaluate the use of novel therapies and incorporation into future guidelines

4 Patient Case AB is a 34 year old African American male who presents to the emergency department with shortness of breath, fatigue, lethargy and a 30 kg weight loss in the past 12 months. Wt 65 kg RR 30 HR 110 BP 105/70 Temp 39 HIV positive, Hepatitis panel negative CD4 60 cells/mm 3, HIV RNA 105,000 copies/ml When should he be started on HAART? What type of HAART regimen is most appropriate?

5 Epidemiology In 2013, 1,242,000 adults and adolescents were living with HIV Estimated 161,200 (13%) were undiagnosed In 2015, 39,514 were diagnosed with HIV infection Six percent (2395) were secondary to injection drug use

6 Epidemiology

7 Epidemiology Virginia: 1 in 115 District of Columbia: 1 in 13

8 Treatment Targets 90% Diagnosed 90% On Treatment 90% Virally Suppressed Closing the treatment gap for children, adolescents and key populations 37% On Treatment Rapidly scale up and early initiation of HIV therapy

9 Early Treatment START: Strategic Timing of Antiretroviral Treatment Objective Population Methods (n=4685) Results Conclusion Risk and benefits of immediate vs. delayed initiation of ART in asymptomatic patients with HIV 18 years old, HIV+, treatment naïve Two CD4 counts 500 cells/mm 3 Immediate initiation of ART vs. Delayed initiation until CD4 350 cells/mm 3 OR condition requiring treatment Primary composite: 42 (immediate) vs. 96 (deferred), HR 0.43; p<0.001 Serious AIDS related event: HR 0.28; p<0.001 Serious non AIDS related event: HR 0.61; p=0.04 Death from any cause: HR 0.58; p=0.13 Immediate initiation of ART was superior to deferred initiation. ART should be recommended in all patients diagnosed with HIV regardless of CD4 count. Lundgren JD, et al. NEJM 2015;373:

10 Early Treatment TEMPRANO: Trial of Early ARVs and Isoniazid Preventive Therapy Objective Evaluate the efficacy of early initiation of ART combined with isoniazid (INH) preventive therapy on reduction of severe illness in HIV infected individuals Population 18 years old, HIV+, CD4 < 800 cells/mm 3 Met no criteria for initiation of ART by WHO guidelines Methods (n= 2056) Results Conclusion Group 1: deferred ART Group 3: early ART Group 2: deferred ART + INH Group 4: early ART + INH Primary composite at 30 months: 11.4% (deferred) vs. 6.6% (early ART); HR 0.56, CI % (no INH) vs. 7.2% (INH); HR 0.65, CI Grade 3 or 4 adverse events, 6 30 months: 7.7% (deferred) vs. 7.1% (early ART) Early initiation of ART and INH preventive therapy independently resulted in 44% lower risk of severe HIV related illness and 35% lower risk of death from any cause. Anglaret X, et al. NEJM 2015;373:808 22

11 Patient Case Patient is diagnosed with PCP and initiated on HAART in the hospital. He presents to a follow up visit at the infectious disease clinic three months after hospitalization Baseline genotype: No mutations Medications: SMX/TMP DS daily and efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) Patient reports he is having vivid dreams and intolerable side effects from his medication, and only takes it about three times weekly Repeat genotype: K103N, Y181C CD4 50 cells/mm 3, HIV RNA 150,000 copies/ml

12 Guidelines Guideline Initiation of HIV therapy Initial Regimen for ART Naive DHHS 2016 ART is recommended for all HIV infected individuals regardless of CD4 count ART is recommended for all individuals to prevent transmission Two NRTIs plus one of the following: INSTI or PI with a booster INSTI based DTG/ABC/3TC DTG + TDF/FTC or TAF/FTC EVG/cobi/TAF/FTC EVG/cobi/TDF/FTC RAL + TDF/FTC or TAF/FTC PI based DRV/r + TDF/FTC or TAF/FTC Department of Health and Human Services tandadolescentgl.pdf. World Health Organization

13 Guidelines Guideline Initiation of HIV therapy Initial Regimen for ART Naive DHHS 2016 WHO 2016 ART is recommended for all HIV infected individuals regardless of CD4 count ART is recommended for all individuals to prevent transmission ART should be initiated in all patients with HIV, regardless of WHO clinical stage and at any CD4 count ART should be initiated in all adults with a WHO clinical status of 3 or 4 and with a CD4 count 350 cells/mm 3 Two NRTIs plus one of the following: INSTI or PI with a booster INSTI based DTG/ABC/3TC DTG + TDF/FTC or TAF/FTC EVG/cobi/TAF/FTC EVG/cobi/TDF/FTC RAL + TDF/FTC or TAF/FTC PI based DRV/r + TDF/FTC or TAF/FTC Two NRTIs plus an NNRTI or INSTI Preferred first line: TDF + 3TC (or FTC) + EFV Alternative first line: ZDV + 3TC + EFV (or NVP) TDF + 3TC (or FTC) + DTG TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + NVP Department of Health and Human Services tandadolescentgl.pdf. World Health Organization

14 Human Immunodeficiency Virus 1. Binding: CCR5 antagonist 2. Fusion: Fusion inhibitor 3. Reverse Transcription: NNRTIs & NRTIs 4. Integration: INSTIs 5. Replication 6. Assembly New Targets? 7. Budding: PIs materials/fact sheets/19/73/the hiv life cycle

15 Human Immunodeficiency Virus 1. Binding: CCR5 antagonist 2. Fusion: Fusion inhibitor 3. Reverse Transcription: NNRTIs & NRTIs 4. Integration: INSTIs 5. Replication 6. Assembly New Targets? 7. Budding: PIs + maturation inhibitors materials/fact sheets/19/73/the hiv life cycle

16 Current HIV Therapies NRTIs NNRTIs PIs INSTIs Other PK Enhancers Abacavir Didanosine Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine Zalcitabine Delavirdine Efavirenz Etravirine Nevirapine Rilpivirine Amprenavir Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir Nelfinavir Saquinavir Tipranavir Dolutegravir Elvitegravir Raltegravir Enfuvirtide Maraviroc Cobicistat Ritonavir and adolescent arv guidelines/292/drug name abbreviations

17 Current HIV Therapies NRTIs NNRTIs PIs INSTIs Other PK Enhancers Abacavir Didanosine Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine Zalcitabine Delavirdine Efavirenz Etravirine Nevirapine Rilpivirine Amprenavir Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir Nelfinavir Saquinavir Tipranavir Dolutegravir Elvitegravir Raltegravir Enfuvirtide Maraviroc Cobicistat Ritonavir and adolescent arv guidelines/292/drug name abbreviations

18 Fixed Dose Combinations (FDCs) ATV/cobi ABC/3TC/ZDV EFV/FTC/TDF EVG/c/FTC/TDF DRV/cobi TC/ZDV ABC/3TC RPV/FTC/TDF DTG/ABC/3TC EVG/c/FTC/TAF FTC/TDF RPV/FTC/TAF FTC/TAF materials/fact sheets/21/58/fda approved hiv medicines

19 Fixed Dose Combinations (FDCs) RPV/TDF/FTC DTG Advantages Easier administration Decreased pill burden Decreased dosing errors Increased adherence Easier access to meds Disadvantages Resistance to first line therapy Difficulty swallowing Side effects Drug interactions DRV/cobi

20 Tenofovir Alafenamide (TAF) Pozniak A, et al. CROI Abstract 795. Seattle, WA

21 Tenofovir Alafenamide (TAF) Properties Tenofovir prodrug with lower plasma concentrations than TDF Significantly more stable in plasma and delivers ~30 times higher concentration intracellularly Development of a prodrug which is selectively hydrolyzed within cells Tenofovir Warnings and Precautions Lactic acidosis and severe hepatomegaly with steatosis New onset or worsening renal impairment Acute renal failure Fanconi syndrome Decreases in bone mineral density Lumbar spine Hip Badowski ME, et al. Infect Dis Ther 2016;5: Viread (tenofovir disoproxil fumarate) package insert. Gilead Sciences, Inc. 2016

22 Tenofovir TAF TDF Indication HIV, HBV* HIV, HBV, PrEP Plasma concentration 80 90% reduction High Intracellular concentration 5.3 fold higher compared to TDF Low Dosing With FTC: 25 mg With EVG/c/FTC: 10 mg 300 mg Renal dosing considerations Adverse event No dosing guidelines for CrCl < 30 ml/min Osteopenia/osteoporosis Nephrotoxicity Only recommended in CrCl > 50 ml/min Osteopenia/osteoporosis Nephrotoxicity Badowski ME, et al. Infect Dis Ther 2016;5:329 52

23 Patient Case Patient is switched from EFV/TDF/FTC to another fixed dose combination tablet EVG/c/TDF/FTC (Stribild) and is tolerating the medication well CD4 100 cells/mm 3, HIV RNA undetectable Serum creatinine: 1.5 mg/dl DEXA: hip 1.5, spine 1.2 Total cholesterol: 210 mg/dl LDL: 150 mg/dl What is the cause of these laboratory abnormalities and are changes to therapy warranted?

24 Tenofovir alafenamide efficacy Tenofovir alafenamide versus tenofovir disoproxil fumarate co formulated with EVG/c/FTC for initial treatment of HIV 1 infection: two randomized, double blind, phase III, non inferiority trials Objective: Methods: Inclusion: Exclusion: Confirm TAF antiviral efficacy and safety Two parallel phase III randomized, double blind, active control, multicenter trials 1:1 randomization to EVG/c/FTC/TAF versus EVG/C/FTC/TDF HIV infected treatment naïve, 18 years old, HIV RNA 1000 copies/ml, egfr 50 ml/min Positive hepatitis B or C, new AIDS defining condition within 30 days Labs: CD4 counts, HIV RNA, serum chemistry, fasting lipid parameters, urine protein evaluation Bone markers: DEXA scans of spine and hip at baseline, week 24 and 48 Primary endpoint: Proportion of patients with HIV RNA < 50 copies/ml at week 48 Sax PE, et al. Lancet 2015;385:

25 Tenofovir alafenamide efficacy Baseline Characteristics EVG/c/FTC/TAF (n=866) EVG/c/FTC/TDF (n=867) Age 33 (26 42) 35 (28 44) Median VL (c/ml) Median CD4 404 ( ) 406 ( ) White 485 (56%) 498 (57%) African heritage 223 (26%) 213 (35%) Median GFR (ml/min) 117 ( ) 114 (99 134) Virologic success (week 48) Primary Outcome 92% TAF vs. 90% TDF, CI 0.7% to 4.7% Study drug discontinuation 0.9% TAF vs. 1.5% TDF Nausea, diarrhea most common overall event Sax PE, et al. Lancet 2015;385:

26 Tenofovir alafenamide efficacy Renal Effects Discontinuation: 0 (TAF) vs. 4 (TDF) Significantly smaller decreases in GFR Quantitative proteinuria in TDF vs. TAF groups Bone Effects No fractures related to study drug Spine: 1.3% vs. 2.86%, p< Hip: 0.66% vs. 2.95%, p< Sax PE, et al. Lancet 2015;385:

27 Tenofovir alafenamide efficacy Conclusion: TAF was non inferior to TDF in virologic suppression and showed favorable renal and bone parameters Interpretation: Patients will be on HAART long term, therefore maximizing the safety of therapy is of utmost importance Limitation: Low number of women, exclusion of hepatitis B or C co infection, less advanced HIV infection, uncertain use for other indications Sax PE, et al. Lancet 2015;385:

28 Tenofovir alafenamide switch studies Switching to TAF/EVG/c/FTC in HIV infected patients with renal impairment Objective Assess safety of EVG/c/FTC/TAF in patients with mild to moderate renal impairment Population Adults, HIV 1 infection, HIV RNA undetectable for 6 months, egfr = ml/min, CKD stable Methods, (n=242) Received EVG/c/FTC/TAF with visits at weeks 1, 2, 4, 8, 12, 16, 24, 36 and 48 Outcomes 1ᵒ: Change from baseline at week 24 in egfr 2ᵒ: Change from baseline at weeks 48 and 96 in egfr, BMD, adverse events, virologic control Results Baseline median egfr = 56 ml/min No clinically appreciable change in egfr Significant improvements in total proteinuria, albuminuria, and tubular proteinuria BMD: Hip and spine: +1.47% and +2.29% (p<0.05) Adverse events: no Fanconi s syndrome or fractures related to study drug Conclusion Interpretation EVG/c/FTC/TAF may be used in patients with mild to moderate renal dysfunction without the need for dose adjustment EVG/C/FTC/TAF (Genvoya) is approved for patients with CrCl 30 ml/min with no dose adjustment Pozniak A, et al. J Acquir Immun Defic Syndrom 2016;71:530 7

29 Salvage Regimen Patient October 2013 August yo Caucasian male Baseline CD4 count 15 cells/mm 3, history of AIDS defining illness (PCP) Treatment history with all approved ART EXCEPT dolutegravir, maraviroc, delavirdine, rilpivirine Started therapy with enfuvirtide + EVG/c/FTC/TDF SCr from 1.47 mg/dl to 4.55 mg/dl; egfr from 53 ml/min to 14 ml/min SCr improves to 2.16 mg/dl after ART discontinuation New regimen: TAF/FTC + dolutegravir + darunavir/r Upon initiation: SCr 1.3 mg/dl 15 months: SCr 1.41 mg/dl, HIV RNA undetectable, CD4 55 cells/mm 3 Conclusion: This case describes the use of TAF in a patient with TDF associated kidney injury and as part of a salvage regimen with the ability to achieve virologic suppression in the setting of six class resistance Mikula JM, et al. Antivir Ther 2016;21:553 8

30 Bone Changes with TAF Switching from TDF to TAF in HIV Infected Adults with Low BMD: A Pooled Analysis Objectives: Determine the % BMD change and T score change at the lumbar spine and total hip over 96 weeks in HIV infected individuals with low BMD Determine baseline factors associated with a clinically significant change in BMD over 96 weeks Methods: On a TDF containing regimen and switched to ELG/c/FTC/TAF versus continue Low BMD (T score 2) at lumbar spine or hip and egfr 50 ml/min Brown T, et al. Poster 683. CROI Seattle, WA. Feb 13 16, 2017.

31 Bone Changes with TAF Conclusions: HIV infected individuals with low BMD switched from TDF to TAF experience: ~2.5% lumbar spine or hip BMD increase over 96 weeks 5% BMD increase in some individuals A reversal from osteoporosis in some individuals Brown T, et al. Poster 683. CROI Seattle, WA. Feb 13 16, 2017.

32 Tenofovir alafenamide formulations Odefsey = TAF + FTC + rilpivirine Indication = HIV 1 infection in patients 12 years old with CrCl 30 ml/min FDA approval March 2016 Not recommended as initial therapy in DHHS guidelines THRIVE Assess non inferiority of rilpivirine to efavirenz Treatment naïve patients with HIV RNA 5000 Backbone of TDF/FTC or ZDV/3TC or ABC/3TC 947 patients enrolled Response 86% (RPV) vs. 82% EFV, p< VL failure 7% (RPV) vs. 5% EFV Adverse events less common with RPV ECHO Assess the efficacy of rilpivirine vs. efavirenz, both combined with TDF/FTC Treatment naïve patients with HIV RNA patients enrolled Response 83% (RPV) vs. 83% (EFV) VL failure 13% (RPV) vs. 6% (EFV) Adverse events 55% (RPV) vs. 31% (EFV), p< Cohen CJ, et al. Lancet 2011;378: Molina JM, et al. Lancet 2011;378: Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) package insert. Gilead Sciences, Inc. 2016

33 Tenofovir alafenamide formulations Odefsey = TAF + FTC + rilpivirine Indication = HIV 1 infection in patients 12 years old with CrCl 30 ml/min FDA approval March 2016 Not recommended as initial therapy in DHHS guidelines Must be administered with a meal Contraindicated with proton pump inhibitors Administer antacids 2 hours before or 4 hours after Odefsey Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) package insert. Gilead Sciences, Inc. 2016

34 Tenofovir alafenamide formulations Descovy = TAF + FTC Indication = HIV 1 infection in patients 12 years old with CrCl 30 ml/min NOT indicated for use as PrEP/PEP to reduce HIV infection risk or perinatal transmission FDA approval April 2016 Preferred NRTI backbone in the DHHS guidelines Differences from TDF/FTC in drug interactions TAF: Category X drug interaction with rifampin and rifabutin Descovy (emtricitabine and tenofovir alafenamide) package insert. Gilead Sciences, Inc. 2016

35 TAF/FTC as PrEP Chemoprophylaxis with oral TAF/FTC prevents macaques from SHIV infection Efficacy in macaques for TAF/FTC for PrEP 12 macaques exposed to rectal SHIV infection once a week for 19 weeks Six received FTC/TAF 24h before and 2h after each exposure All six remained seronegative through 10 week follow up, all six placebos were SHIV positive Concentrations of TFV in female mucosal tissue after a single dose of TAF 100 fold higher TFV concentrations in colorectal tissue may contribute to PrEP advantages in men vs. women Phase I PK study in eight healthy women In comparison to TDF, TAF plasma AUC was 95% lower TAF was undetectable in tissue Cellular concentrations were 808% higher Massud I, et al. CROI Abstract 107. Boston, MA Garrett KL, et al. CROI Abstract 102LB. Boston, MA

36 TAF single formulation Currently available only as fixed dose combinations November 10, 2016 FDA approved Vemlidy for treatment of chronic hepatitis B TAF versus TDF for the treatment of patients with chronic Hep B infection Randomized, double blind, phase III, non inferiority trial Patients 18 years old, HBV DNA > 20,000 IU/mL, CrCl 50 ml/min, ALT < ten times upper limit of normal Primary endpoint: patients with HBV DNA < 29 IU/mL at 48 weeks 426 patients met inclusion criteria 94% (TAF) vs. 93% TDF with success at week 48, p=0.47 TAF was non inferior to TDF and had improved renal and bone effects Buti M, et al. Lancet Gastroenterol Hepatol 2016;1: Vemlidy (tenofovir alafenamide) package insert. Gilead Sciences, Inc. 2016

37 TAF single formulation Indication Testing Dosing Administration Warnings TAF for hepatitis B Treatment of chronic hepatitis B in adults with compensated liver disease Prior to initiation patients should be tested for HIV infection 25 mg once daily, no dosage adjustment in mild, moderate or severe renal impairment Not recommended in CrCl < 15 ml/min Not recommended in Child Pugh class B or C hepatic impairment Taken once daily orally with food Lactic acidosis/severe hepatomegaly with steatosis Severe acute exacerbation of hepatitis B after discontinuation of treatment Risk of developing HIV resistance in co infected patients New onset or worsening renal impairment Adverse Reactions Headache (9%), abdominal pain (7%), fatigue (6%), cough (6%), nausea (5%), back pain (5%) Pricing $ (#30) Vemlidy (tenofovir alafenamide) package insert. Gilead Sciences, Inc. 2016

38 TAF Dosing TAF TDF Genvoya TAF 10 mg FTC 200 mg Cobi 150 mg EVG 150 mg Stribild TDF 300 mg FTC 200 mg Cobi 150 mg EVG 150 mg Odefsey TAF 25 mg FTC 200 mg RPV 15 mg Complera TDF 300 mg FTC 200 mg RPV 25 mg Descovy TAF 25 mg FTC 200 mg Truvada TDF 300 mg FTC 200 mg Vemlidy TAF 25 mg Viread TDF 300 mg

39 Safety Concerns ISMP Safety Alert Two reports received about electronic health record displays of Genvoya and Stribild Computer used abbreviation: Elviteg Cobic Emtricit TenofAF Stribild was mistakenly dispensed Display brand AND generic and do not abbreviate Products are NOT interchangeable ISMP 2016;21:1 4

40 Future Uses Perinatal PrEP PEP

41 Pipeline Therapies

42 Cabotegravir Pharmacology Integrase strand transfer inhibitor Structural analog of dolutegravir Formulated as both an oral tablet and a long acting suspension injectable Half life = 40 hours (oral dosing) Investigated in combination with rilpivirine LATTE I Long Acting Antiretroviral Treatment Enabling Objective Assess viral suppression of cabotegravir + NRTIs compared with EFV + NRTIS followed by assessment of cabotegravir + RPV as two drug treatment regimen Population Age 18, HIV RNA 1000 copies/ml, CD4 200 cells/mm 3, ART naïve, no major mutations Methods (n=243) 24 week induction: 1:1:1:1 to cabotegravir 10 mg, 30 mg, or 60 mg once daily or EFV 600 mg once daily with ABC/3TC or TDF/FTC 72 week maintenance (207 patients): Cabotegravir dose continued with RPV 25 mg and no NRTIs Results Viral response 86% (CAB) vs. 74% (EFV), p< At 72 weeks 76% (CAB + RPV) vs. 63% (EFV) Virologic suppression numerically higher through 96 weeks Efficacy lends support to cabotegravir 30 mg daily Conclusion As a two drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activity similar to EFV + NRTIs at week 96 Trezza C, et al. Curr Opin HIV AIDS 2015;10: Margolis DA, et al. Lancet Infect Dis 2015;15:

43 Cabotegravir LATTE II Phase IIb study, multicenter, parallel group, open label Induction phase with 30 mg cabotegravir + ABC/3TC 2:2:1 randomization to IM CAB LA + RPV LA every 4 weeks, 8 weeks, or remained on oral therapy 309 patients enrolled Week 32: 95% (q8week), 94% (q4week) and 91% (oral) maintained viral suppression 92% had injection site pain, otherwise well tolerated Concerns with Use and Potential Role Scheduled visits to receive injections Patient adherence Reversal in the case of hypersensitivity PK parameters in real world population Susceptibility of virus to cabotegravir + coformulated agent PrEP in certain populations? Margolis DA, et al. CROI Abstract 31LB. Boston, MA Margolis DA, et al. Curr Opin HIV AIDS 2015;10:246 52

44 Doravirine Pharmacology Doravirine non inferior to darunavir in phase III treatmentnaïve trial at week 48 Design Phase III, multicenter, double blind, non inferiority Non nucleoside reverse transcriptase inhibitor Selects for distinct mutations in vitro: V106A, F227L, L234I Limited cross resistance between other NNRTIs Does not inhibit or induce CYP enzymes May be taken without regard to food Population Methods (n=766) Objective Results Conclusion HIV infected treatment naïve with >1000 copies/ml 1:1 randomization to doravirine 100 mg daily or DRV/r 800/100 mg daily plus TDF/FTC or ABC/3TC Proportion with HIV RNA < 50 copies/ml Effects on fasting lipids Virologic suppression: 83.8% doravirine vs. 79.9% darunavir, diff 3.9% ( 1.6, 9.4) Adverse reactions (DOR, DRV): Diarrhea (5.5%, 12.8%), nausea (6.5%, 7.6%), headache (6.0%, 2.6%) At week 48, doravirine was non inferior to darunavir on a background of 2 NRTIs in HIV treatment naïve adults. DOR was safe and well tolerated with a superior lipid profile. Badowski ME, et al. Infect Dis Ther 2016;5: Squires K, et al. Oral abstract 45LB. CROI Seattle, WA. Feb 13 16, 2017

45 Ibalizumab Pharmacology Humanized murine monoclonal antibody Binds to the interface between domain 1 and 2 on CD4 cell (does not bind to gp 120) Conformational changes that prevent gp120 from interacting with CCR5 or CXCR4 Antiviral activity regardless of tropism No immunosuppressive effects seen Bruno, et al. J Antimicrob Chemother 2010;65:

46 Ibalizumab Long acting ibalizumab in patients with multi drug resistant HIV 1: A 24 week study Design Population Methods (n=40) Single arm, 24 week study HIV 1 infected, treatment experienced, failing current regimen, documented resistance Loading dose: 2000 mg IBA IV Maintenance: 800 mg IBA IV every 2 weeks for 24 weeks OBR added on day 14 (sensitivity to at least 1 agent) Objective Primary: Patients with 0.5 log 10 decrease in VL at day 14 Results Conclusion IBA = ibalizumab OBR = optimized background regimen Mean VL decrease of 1.6 from baseline 55% and 48% with a 1 and 2 log 10 reduction UD VL in 43% of patients In treatment experienced patients with few treatment options, IBA plus OBR maintained virologic efficacy and was well tolerated Lewis S, et al. Poster 449LB. CROI Seattle, WA. Feb 13 16, 2017

47 Ibalizumab IV vs. IM His Hsun, L, et al. Poster 438. CROI Seattle, WA. Feb 13 16, 2017

48 Mono and Dual Therapy Case Series Meta analysis, n=87 DTG monotherapy in long term virologic suppression Comorbidities, drug interactions, adverse effects, resistance Virologic suppression 91.9%, failure 8.1% 4/5 patients with failure had prior INSTI exposure DOLOMONO Multicenter randomized trial Comparing DTG monotherapy vs. continued ART (cart) HIV positive, VL < 50 copies/ml, no history virologic failure Primary endpoint: VL < 200 copies/ml at week weeks: 92/94 on DTG monotherapy with VL < weeks: 77/94 patients, virologic failure in 8 Led to premature study discontinuation as integrase resistance found in 3 of 6 when testing could be performed DTG Monotherapy: When should clinical practice be clinical research? Moreira J. J Antimicrob Chemother 2016;71: Wijting I, et al. Poster 451LB. CROI Seattle, WA. Feb 13 16, 2017 Gallant J. Antivir Ther 2016:Dec 15

49 Dual Therapy LAMIDOL Ongoing, open label, single arm trial, multicenter trial DTG (50 mg) + 3TC (300 mg) daily On 2 NRTIs + PI, NNRTI, or INSTI CD4 nadir > 200, HIV RNA < 50 for 2 years 104 patients switched to DTG 3TC 1 patient with virologic failure at 24 weeks of dual therapy DTG 3TC well tolerated and effective at 24 weeks in virologically suppressed patients SWORD SWORD 1 and SWORD 2 Switching to dual therapy from 3 or 4 drug regimens HIV RNA < 50 for 12 months 148 week, randomized, open label, noninferiority Met non inferiority endpoint at week 48 VL < 50 copies/ml SWORD 1: 95% vs. 96% SWORD 2: 94% vs. 95% No patients developed integrase mutations Joly V, et al. Poster 458. CROI Seattle, WA. Feb 13 16, 2017 Llibre J, et al. Oral abstract 44LB. CROI Seattle, WA. Feb 13 16, 2017

50 Future Directions HIV maturation inhibitor HIV vaccination Toll like receptor agonist CCR5 monoclonal antibody

51 Learning Assessment Question 1: The DHHS 2016 guideline updates include which of the following as a recommended regimen for ART naïve patients? a) ATZ + TDF/FTC b) EFV + TDF/FTC c) EVG/cobi + TDF/FTC OR TAF/FTC d) LPV + TDF/FTC Answer: C Found on slides 11/12

52 Learning Assessment Question 2: Tenofovir alafenamide differs from tenofovir disoproxil fumarate in which of the following principles? a) TAF delivers 30 times higher concentrations intracellularly b) TDF delivers 30 times higher concentrations intracellularly c) TAF is a prodrug of tenofovir and TDF not a prodrug d) TAF has no risk of development of Fanconi syndrome Answer: A Found on slide 20

53 Learning Assessment Question 3: Ibalizumab is a pipeline HIV therapy which works by which of the following mechanisms? a) Binds to the gp120 subunit to prevent HIV entry into CD4 cells b) CCR5 antagonist preventing HIV entry into CD4 cells c) Binds to the domain 1 and 2 interface on CD4 cells d) Monoclonal antibody in a subcutaneous formulation Answer: C Found on slide 44

54 A Changing Landscape: New and Pipeline HIV Therapies Sarah Turley, PharmD, BCPS PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health System

55 Abbreviations 3TC = lamivudine ABC = abacavir ATV = atazanavir CAB = cabotegravir COBI or c = cobicistat DRV = darunavir DTG = dolutegravir EFV = efavirenz EVG = elvitegravir FTC = emtricitabine INSTI = integrase strand transfer inhibitor Medications NRTI = nucleoside reverse transcriptase inhibitor NNRTI = non nucleoside reverse transcriptase inhibitor NVP = nevirapine PI = protease inhibitor RAL = raltegravir RPV = rilpivirine RTV or r = ritonavir TAF = tenofovir alafenamide TDF = tenofovir disoproxil fumarate TFV = tenofovir ZDV = zidovudine Other AIDS = acquired immunodeficiency virus ART = antiretroviral therapy ARV = antiretroviral FDC = fixed dose combination HAART = highly active antiretroviral therapy HIV = human immunodeficiency virus MSM = men who have sex with men PEP = post exposure prophylaxis PrEP = pre exposure prophylaxis and adolescent arv guidelines/292/drug name abbreviations

56 Brand Generic: FDCs ABC + 3TC + ZDV ABC + 3TC FTC + TDF EFV + FTC + TDF RPV + FTC + TDF ELV + cobi + FTC + TDF ABC + 3TC + DTG ATZ + cobi DRV + cobi ELV + cobi + FTC + TAF RPV + FTC + TAF FTC + TAF Trizivir Epzicom Truvada Atripla Complera Stribild Triumeq Evotaz Prezcobix Genvoya Odefsey Descovy

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

Disclosures (last 12 months)

Disclosures (last 12 months) HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,

More information

Starting and Switching ART: 2016

Starting and Switching ART: 2016 Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,

More information

ARVs in Development: Where do they fit?

ARVs in Development: Where do they fit? The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

Actualización y Futuro en VIH

Actualización y Futuro en VIH Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral

More information

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Didactic Series. Switching Regimens in the Setting of Virologic Suppression Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines

More information

Antiretroviral Therapy: What to Start

Antiretroviral Therapy: What to Start FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,

More information

Medication Errors Focus on the HIV-Infected Patient

Medication Errors Focus on the HIV-Infected Patient Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

CROI 2013: New Drugs for Treatment and PrEP

CROI 2013: New Drugs for Treatment and PrEP NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington

More information

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015

DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects

More information

HIV Treatment: New and Veteran Drugs Classes

HIV Treatment: New and Veteran Drugs Classes HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are

More information

Tenofovir Alafenamide (TAF)

Tenofovir Alafenamide (TAF) Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016

More information

HIV Treatment: State of the Art 2013

HIV Treatment: State of the Art 2013 HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

The next generation of ART regimens

The next generation of ART regimens The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state

More information

Sculpting a Better Regimen: The ART of HIV Medications

Sculpting a Better Regimen: The ART of HIV Medications Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members

More information

ART: The New, The Old and The Ugly

ART: The New, The Old and The Ugly ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine

More information

Treatment update. Bronagh McBrien June 2016

Treatment update. Bronagh McBrien June 2016 Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA

More information

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to: CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer

More information

Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC

Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,

More information

The ART of Managing Drug-Drug Interactions in Patients with HIV

The ART of Managing Drug-Drug Interactions in Patients with HIV The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko

HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections

More information

Antiretroviral Drugs

Antiretroviral Drugs Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &

More information

Pharmacological considerations on the use of ARVs in pregnancy

Pharmacological considerations on the use of ARVs in pregnancy Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl

More information

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures

More information

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

SELECTING THE BEST ART FOR EACH PATIENT

SELECTING THE BEST ART FOR EACH PATIENT SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May

More information

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

treatment passport 1

treatment passport 1 treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor

More information

INTERGRASE INHIBITORS- WHAT S NEW?

INTERGRASE INHIBITORS- WHAT S NEW? INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4

More information

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /

More information

HIV Management Update 2015

HIV Management Update 2015 9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe

More information

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners

More information

HIV 101. Applications of Antiretroviral Therapy

HIV 101. Applications of Antiretroviral Therapy HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,

More information

Didactic Series. CROI 2014 Update. March 27, 2014

Didactic Series. CROI 2014 Update. March 27, 2014 Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,

More information

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1 MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at

More information

HIV - Therapy Principles

HIV - Therapy Principles HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV

More information

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and

More information

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

Approach for the Newly Diagnosed HIV Positive Patient

Approach for the Newly Diagnosed HIV Positive Patient Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology

More information

ANTIRETROVIRAL TREATMENTS (Part 1of

ANTIRETROVIRAL TREATMENTS (Part 1of CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after

More information

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018 The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

Disclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:

Disclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation: Disclosures Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 8, 2017 Research grant support from Gilead Sciences for ongoing work

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

Descovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow

Descovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow Descovy (emtricitabine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Descovy Generic name: Emtricitabine, tenofovir alafenamide (TAF) Pharmacological class: Nucleoside analog reverse

More information

Dolutegravir-Rilpivirine (Juluca)

Dolutegravir-Rilpivirine (Juluca) Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL

More information

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H. Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community

More information

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

CROI 2017 Review: Novel ART Strategies

CROI 2017 Review: Novel ART Strategies Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Exploring HIV in 2017: What a pharmacist needs to know

Exploring HIV in 2017: What a pharmacist needs to know Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,

More information

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious

More information

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in

More information

1/13/16. Updated April 2015

1/13/16.   Updated April 2015 Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify

More information

Cases from the Clinic(ians): Case-Based Panel Discussion

Cases from the Clinic(ians): Case-Based Panel Discussion Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,

More information

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,

More information

Antiretroviral Therapy in 2016

Antiretroviral Therapy in 2016 Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory

More information

Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era

Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon

More information

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University

More information

L infettivologia del 3 millennio: AIDS ed altro

L infettivologia del 3 millennio: AIDS ed altro L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie

More information

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com

More information

Integrase Strand Transfer Inhibitors on the Horizon

Integrase Strand Transfer Inhibitors on the Horizon NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation

More information

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role

More information

HIV Treatment Update. Objectives. Epidemiology 12/22/2015

HIV Treatment Update. Objectives. Epidemiology 12/22/2015 HIV Treatment Update Monique Calil, Pharm.D. PGY-1 Resident Broward Health Medical Center Objectives Review antiretroviral therapy (ART) medications used for the treatment of HIV, including new combination

More information

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,

More information

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

Stribild, a Single Tablet Regimen for the Treatment of HIV Disease

Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com

More information

HIV in in Women Women

HIV in in Women Women HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732

More information

Starting Immediate Treatment for HIV-1

Starting Immediate Treatment for HIV-1 Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation

More information

Antiretroviral Treatment 2014

Antiretroviral Treatment 2014 Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon

More information

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of

More information

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1 Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,

More information

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,

More information

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,

More information

Important new concerns or changes to the current ones will be included in updates of Symtuza's RMP.

Important new concerns or changes to the current ones will be included in updates of Symtuza's RMP. Summary of Risk Management Plan for Symtuza (D/C/F/TAF) This is a summary of the risk management plan (RMP) for Symtuza. The RMP details important risks of Symtuza, how these risks can be minimised, and

More information

Matters of the HAART: An Update on Current Treatment Options for HIV

Matters of the HAART: An Update on Current Treatment Options for HIV Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Switching antiretroviral therapy to safer strategies based on integrase inhibitors

Switching antiretroviral therapy to safer strategies based on integrase inhibitors Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical

More information

Vemlidy. (tenofovir alafenamide) New Product Slideshow

Vemlidy. (tenofovir alafenamide) New Product Slideshow Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength

More information